Evidence map›Paper›PMID 36080388›Full record

ArticleMolecules (Basel, Switzerland)2022

Synthesis, Leishmanicidal, Trypanocidal, Antiproliferative Assay and Apoptotic Induction of (2-Phenoxypyridin-3-yl)naphthalene-1(2

Zuleima Blanco, Esteban Fernandez-Moreira, Michael R Mijares, Carmen Celis, Gricelis Martínez, Juan B De Sanctis, Soňa Gurská, Petr Džubák, Marián Hajdůch, Ali Mijoba and 8 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zuleima BlancoOrganic Synthesis Laboratory, Faculty of Pharmacy, Central University of Venezuela, Los Chaguaramos 1041-A, Caracas 47206, Venezuela.
Esteban Fernandez-MoreiraEscuela de Medicina, Universidad Espíritu Santo, Samborondón 092301, Ecuador.
Michael R MijaresBiotechnology Unit, Faculty of Pharmacy, Central University of Venezuela, Los Chaguaramos 1041-A, Caracas 47206, Venezuela.
Carmen CelisBiotechnology Unit, Faculty of Pharmacy, Central University of Venezuela, Los Chaguaramos 1041-A, Caracas 47206, Venezuela.
Gricelis MartínezBiotechnology Unit, Faculty of Pharmacy, Central University of Venezuela, Los Chaguaramos 1041-A, Caracas 47206, Venezuela.ORCID 0000-0002-8204-0174
Juan B De SanctisInstitute of Immunology, Faculty of Medicine, Central University of Venezuela, Los Chaguaramos 1050-A, Caracas 50109, Venezuela.ORCID 0000-0002-5480-4608
Soňa GurskáInstitute of Molecular and Translational Medicine, Faculty of Medicine, Palacky University, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic.
Petr DžubákInstitute of Molecular and Translational Medicine, Faculty of Medicine, Palacky University, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic.ORCID 0000-0002-3098-5969
Marián HajdůchInstitute of Molecular and Translational Medicine, Faculty of Medicine, Palacky University, Hněvotínská 1333/5, 77900 Olomouc, Czech Republic.ORCID 0000-0002-4834-908X
Ali MijobaLaboratory of Biology and Chemotherapy of Tropical Parasitosis of the Foundation Institute for Advanced Studies (IDEA) Health Area, Caracas 1080, Venezuela.ORCID 0000-0002-8061-9625
Yael GarcíaLaboratory of Biology and Chemotherapy of Tropical Parasitosis of the Foundation Institute for Advanced Studies (IDEA) Health Area, Caracas 1080, Venezuela.
Xenón SerranoLaboratory of Biology and Chemotherapy of Tropical Parasitosis of the Foundation Institute for Advanced Studies (IDEA) Health Area, Caracas 1080, Venezuela.
Nahum HerreraGrupo de Investigación en Moléculas y Materiales Funcionales (MoléMater), Dirección de Investigación, Universidad Central del Ecuador, Jerónimo Leiton s/n y Gilberto Gatto Sobral, Quito 170521, Ecuador.ORCID 0000-0001-9810-2192
Jhonny Correa-AbrilGrupo de Investigación en Moléculas y Materiales Funcionales (MoléMater), Dirección de Investigación, Universidad Central del Ecuador, Jerónimo Leiton s/n y Gilberto Gatto Sobral, Quito 170521, Ecuador.ORCID 0000-0002-6949-1923
Yonathan ParraGrupo de Investigación en Moléculas y Materiales Funcionales (MoléMater), Dirección de Investigación, Universidad Central del Ecuador, Jerónimo Leiton s/n y Gilberto Gatto Sobral, Quito 170521, Ecuador.ORCID 0000-0002-0284-3234
Jorge ÁngelLaboratorio de Síntesis Orgánica y Diseño de Fármacos, Department de Química, Facultad Experimental de Ciencias, Universidad del Zulia, Maracaibo 4001, Venezuela.
Hegira RamírezUniversidad ECOTEC, Km. 13.5 Vía Samborondón, Guayaquil 092302, Ecuador.ORCID 0000-0003-1916-6118
Jaime E CharrisOrganic Synthesis Laboratory, Faculty of Pharmacy, Central University of Venezuela, Los Chaguaramos 1041-A, Caracas 47206, Venezuela.ORCID 0000-0003-4404-2619

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coexistence of leishmaniasis, Chagas disease, and neoplasia in endemic areas has been extensively documented. The use of common drugs in the treatment of these pathologies invites us to search for new molecules with these characteristics. In this research, we report 16 synthetic chalcone derivatives that were investigated for leishmanicidal and trypanocidal activities as well as for antiproliferative potential on eight human cancers and two nontumor cell lines. The final compounds 8−23 were obtained using the classical base-catalyzed Claisen−Schmidt condensation. The most potent compounds as parasiticidal were found to be 22 and 23, while compounds 18 and 22 showed the best antiproliferative activity and therapeutic index against CCRF-CEM, K562, A549, and U2OS cancer cell lines and non-toxic VERO, BMDM, MRC-5, and BJ cells. In the case of K562 and the corresponding drug-resistant K562-TAX cell lines, the antiproliferative activity has shown a more significant difference for compound 19 having 10.3 times higher activity against the K562-TAX than K562 cell line. Flow cytometry analysis using K562 and A549 cell lines cultured with compounds 18 and 22 confirmed the induction of apoptosis in treated cells after 24 h. Based on the structural analysis, these chalcones represent new compounds potentially useful for Leishmania, Trypanosoma cruzi, and some cancer treatments.

Indexed as

Chagas DiseaseChalconeLeishmaniaLeishmaniasisTrypanocidal AgentsTrypanosoma cruziHumansNaphthalenesStructure-Activity RelationshipChalconeNaphthalenesTrypanocidal AgentsapoptosiscancerchalconeLeishmaniasisTrypanosoma cruzi

Identifiers

PMID36080388
PMCPMC9457600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.